` 000100 (Yuhan Corp) vs KOSPI 200 Comparison - Alpha Spread

000100
vs
KOSPI 200

Over the past 12 months, has significantly outperformed KOSPI 200, delivering a return of 58% compared to the KOSPI 200's 8% drop.

Stocks Performance
000100 vs KOSPI 200

Loading

Performance Gap
000100 vs KOSPI 200

Loading
000100
KOSPI 200
Difference

Performance By Year
000100 vs KOSPI 200

Loading
000100
KOSPI 200
Add Stock

Competitors Performance
Yuhan Corp vs Peers

KOSPI 200
000100
LLY
JNJ
NOVO B
ROG
Add Stock

Yuhan Corp
Glance View

Market Cap
8.5T KRW
Industry
Pharmaceuticals

In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.

Intrinsic Value
58 796.31 KRW
Overvaluation 49%
Intrinsic Value
Price
Back to Top